-
公开(公告)号:EP0402646B1
公开(公告)日:1998-07-22
申请号:EP90109319.5
申请日:1990-05-17
Applicant: ABBOTT LABORATORIES
Inventor: Kempf, Dale J. , Norbeck, Daniel W. , Erickson, John W. , Codacovi, Lynn M. , Sham, Hing Leung , Plattner, Jacob J.
IPC: C07D213/40 , C07D213/56 , C07D211/44 , C07D215/14 , C07D211/34 , C07D215/18 , C07D295/26 , C07D295/145 , C07D303/04 , C07D303/23 , C07D303/36
CPC classification number: C07D207/08 , A61K38/00 , C07C33/46 , C07C43/164 , C07C43/1742 , C07C43/2055 , C07C43/215 , C07C43/23 , C07C43/30 , C07C43/315 , C07C45/004 , C07C45/29 , C07C45/567 , C07C45/59 , C07C45/62 , C07C45/673 , C07C45/74 , C07C53/134 , C07C69/34 , C07C69/65 , C07C69/732 , C07C211/27 , C07C215/18 , C07C215/20 , C07C215/28 , C07C229/08 , C07C229/26 , C07C229/34 , C07C233/36 , C07C233/40 , C07C235/10 , C07C235/12 , C07C235/34 , C07C235/78 , C07C237/10 , C07C237/20 , C07C237/22 , C07C239/10 , C07C239/18 , C07C239/20 , C07C247/10 , C07C251/40 , C07C271/20 , C07C271/22 , C07C271/34 , C07C275/16 , C07C275/24 , C07C311/03 , C07C311/13 , C07C311/18 , C07C317/10 , C07C317/28 , C07C317/44 , C07C323/12 , C07C323/25 , C07C381/00 , C07C2601/14 , C07D207/24 , C07D209/42 , C07D211/62 , C07D213/30 , C07D213/40 , C07D213/42 , C07D213/56 , C07D213/70 , C07D213/81 , C07D213/82 , C07D215/16 , C07D217/16 , C07D217/26 , C07D231/12 , C07D233/56 , C07D233/84 , C07D239/38 , C07D249/08 , C07D263/32 , C07D277/24 , C07D277/28 , C07D277/36 , C07D277/42 , C07D277/56 , C07D295/088 , C07D295/15 , C07D295/155 , C07D295/185 , C07D295/205 , C07D295/215 , C07D295/26 , C07D303/04 , C07D303/22 , C07D303/36 , C07D303/48 , C07D307/42 , C07D317/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07F9/3241 , C07F9/5333 , C07K5/021 , C07K5/06043 , C07K5/06052 , C07K5/06139 , Y02P20/55 , C07C49/233 , C07C49/255 , C07C49/215 , C07C49/245 , C07C49/235 , C07C49/223
-
2.Intermediates for preparating non-peptide retroviral protease inhibitors 失效
Title translation: Zvischenprodukte zur Herstellung von non-peptiden retroviralproteasehemmenden Verbindungen公开(公告)号:EP0839798A2
公开(公告)日:1998-05-06
申请号:EP97119700.9
申请日:1990-05-17
Applicant: ABBOTT LABORATORIES
Inventor: Kempf, Dale J. , Norbeck, Daniel W. , Erickson, John W. , Sham, Hing Leung , Codacovi, Lynn M. , Plattner, Jacob J.
IPC: C07C215/18 , C07C271/20 , C07C237/10 , C07D303/40 , C07D303/46
CPC classification number: C07D207/08 , A61K38/00 , C07C33/46 , C07C43/164 , C07C43/1742 , C07C43/2055 , C07C43/215 , C07C43/23 , C07C43/30 , C07C43/315 , C07C45/004 , C07C45/29 , C07C45/567 , C07C45/59 , C07C45/62 , C07C45/673 , C07C45/74 , C07C53/134 , C07C69/34 , C07C69/65 , C07C69/732 , C07C211/27 , C07C215/18 , C07C215/20 , C07C215/28 , C07C229/08 , C07C229/26 , C07C229/34 , C07C233/36 , C07C233/40 , C07C235/10 , C07C235/12 , C07C235/34 , C07C235/78 , C07C237/10 , C07C237/20 , C07C237/22 , C07C239/10 , C07C239/18 , C07C239/20 , C07C247/10 , C07C251/40 , C07C271/20 , C07C271/22 , C07C271/34 , C07C275/16 , C07C275/24 , C07C311/03 , C07C311/13 , C07C311/18 , C07C317/10 , C07C317/28 , C07C317/44 , C07C323/12 , C07C323/25 , C07C381/00 , C07C2601/14 , C07D207/24 , C07D209/42 , C07D211/62 , C07D213/30 , C07D213/40 , C07D213/42 , C07D213/56 , C07D213/70 , C07D213/81 , C07D213/82 , C07D215/16 , C07D217/16 , C07D217/26 , C07D231/12 , C07D233/56 , C07D233/84 , C07D239/38 , C07D249/08 , C07D263/32 , C07D277/24 , C07D277/28 , C07D277/36 , C07D277/42 , C07D277/56 , C07D295/088 , C07D295/15 , C07D295/155 , C07D295/185 , C07D295/205 , C07D295/215 , C07D295/26 , C07D303/04 , C07D303/22 , C07D303/36 , C07D303/48 , C07D307/42 , C07D317/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07F9/3241 , C07F9/5333 , C07K5/021 , C07K5/06043 , C07K5/06052 , C07K5/06139 , Y02P20/55 , C07C49/233 , C07C49/255 , C07C49/215 , C07C49/245 , C07C49/235 , C07C49/223
Abstract: Intermediates, for preparing non-peptide retroviral protease inhibitors, said intermediates having the formula:
or an acid addition salt thereof or an N-protected derivative thereof wherein at each occurrence the N-protecting group is independently selected from the group consisting of formyl, acetyl, pivaloyl, t-butylacetyl, t-butyloxycarbonyl, benzyloxycarbonyl, benzyl and isopropylaminocarbonyl; or said intermediates being selected from:
(2S,3R,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3S,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3R,4R,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3S,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3R,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3R,4R,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3S,4R,5S)-2-(N-(t-butyloxy)carbonyl)amino)-5-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
2-(N-benzyl-N-(benzyloxycarbonyl)amino)-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide;
2-amino-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; and
2,5-di-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide;
or an acid addition salt thereof.Abstract translation: 用于制备非肽逆转录病毒蛋白酶抑制剂的所述中间体,所述具有下式的中间体:其中在每次出现时,N-保护基团独立地选自由以下基团组成的组: 甲酰基,乙酰基,新戊酰基,叔丁基乙酰基,叔丁氧基羰基,苄氧羰基,苄基和异丙基氨基羰基; 或所述中间体选自:(2S,3R,4S,5S)-2,5-二 - (N-(Cbz-缬氨基)氨基)-3,4-二羟基-1,6-二苯基己烷; (2S,3S,4S,5S)-2,5-二 - (N-(Cbz-缬氨基)氨基)-3,4-二羟基-1,6-二苯基己烷; (2S,3R,4R,5S)-2,5-二(N-(Cbz-缬氨基)氨基)-3,4-二羟基-1,6-二苯基己烷; (2S,3S,4S,5S)-2,5-二 - (N-(缬氨酰基)氨基)-3,4-二羟基-1,6-二苯基己烷; (2S,3R,4S,5S)-2,5-二 - (N-(缬氨基)氨基)-3,4-二羟基-1,6-二苯基六氢; (2S,3R,4R,5S)-2,5-二 - (N-(缬氨酰基)氨基)-3,4-二羟基-1,6-二苯基己烷; (2S,3S,4R,5S)-2-(N-(叔丁氧基)羰基)氨基)-5-(N-(Cbz-缬氨酰基)氨基)-3,4-二羟基-1,6-二苯基己烷; 2-(N-苄基-N-(苄氧基羰基)氨基)-5-(叔丁氧基羰基氨基)-1,6-二苯基-3-己烯-3,4-氧化物; 2-氨基-5-(叔丁氧羰)-1,6-二苯基 - 3-己烯-3,4-氧化物; 和2,5-二(叔丁氧基羰基氨基)-1,6-二苯基-3-己烯-3,4-氧化物; 或其酸加成盐。
-
公开(公告)号:EP0402646A1
公开(公告)日:1990-12-19
申请号:EP90109319.5
申请日:1990-05-17
Applicant: ABBOTT LABORATORIES
Inventor: Kempf, Dale J. , Norbeck, Daniel W. , Erickson, John W. , Codacovi, Lynn M. , Sham, Hing Leung , Plattner, Jacob J.
IPC: C07D213/40 , C07D213/56 , C07D211/44 , C07D215/14 , C07D211/34 , C07D215/18 , C07D295/26 , C07D295/145 , C07D303/04 , C07D303/23 , C07D303/36
CPC classification number: C07D207/08 , A61K38/00 , C07C33/46 , C07C43/164 , C07C43/1742 , C07C43/2055 , C07C43/215 , C07C43/23 , C07C43/30 , C07C43/315 , C07C45/004 , C07C45/29 , C07C45/567 , C07C45/59 , C07C45/62 , C07C45/673 , C07C45/74 , C07C53/134 , C07C69/34 , C07C69/65 , C07C69/732 , C07C211/27 , C07C215/18 , C07C215/20 , C07C215/28 , C07C229/08 , C07C229/26 , C07C229/34 , C07C233/36 , C07C233/40 , C07C235/10 , C07C235/12 , C07C235/34 , C07C235/78 , C07C237/10 , C07C237/20 , C07C237/22 , C07C239/10 , C07C239/18 , C07C239/20 , C07C247/10 , C07C251/40 , C07C271/20 , C07C271/22 , C07C271/34 , C07C275/16 , C07C275/24 , C07C311/03 , C07C311/13 , C07C311/18 , C07C317/10 , C07C317/28 , C07C317/44 , C07C323/12 , C07C323/25 , C07C381/00 , C07C2601/14 , C07D207/24 , C07D209/42 , C07D211/62 , C07D213/30 , C07D213/40 , C07D213/42 , C07D213/56 , C07D213/70 , C07D213/81 , C07D213/82 , C07D215/16 , C07D217/16 , C07D217/26 , C07D231/12 , C07D233/56 , C07D233/84 , C07D239/38 , C07D249/08 , C07D263/32 , C07D277/24 , C07D277/28 , C07D277/36 , C07D277/42 , C07D277/56 , C07D295/088 , C07D295/15 , C07D295/155 , C07D295/185 , C07D295/205 , C07D295/215 , C07D295/26 , C07D303/04 , C07D303/22 , C07D303/36 , C07D303/48 , C07D307/42 , C07D317/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07F9/3241 , C07F9/5333 , C07K5/021 , C07K5/06043 , C07K5/06052 , C07K5/06139 , Y02P20/55 , C07C49/233 , C07C49/255 , C07C49/215 , C07C49/245 , C07C49/235 , C07C49/223
Abstract: A retroviral protease inhibiting compound of the formula
or a pharmaceutical acceptable salt, prodrug or ester thereof, wherein X is a linking group;
A is
(1) substituted amino,
(2) substituted carbonyl,
(3) functionalized imino,
(4) functionalized alkyl,
(5) functionalized acyl,
(6) functionalized heterocyclic or
(7) functionalized (heterocyclic)alkyl; and B is
(1) substituted carbonyl independently defined as herein,
(2) substituted amino independently defined as herein,
(3) functionalized imino independently defined as herein,
(4) functionalized alkyl independently defined as herein,
(5) functionalized acyl independently defined as herein,
(6) functionalized heterocyclic independently defined as herein or
(7) functionalized (heterocyclic)alkyl independently defined as herein.Abstract translation: 式A-X-B的逆转录病毒蛋白酶抑制化合物或其药学上可接受的盐,前药或酯,其中X是连接基团; A是(1)取代氨基,(2)取代羰基,(3)官能化亚氨基,(4)官能化烷基,(5)官能化酰基,(6)官能化杂环或(7)官能化(杂环)烷基; 并且B是本文独立定义的(1)取代的羰基,(2)独立地定义如本文的取代氨基,(3)如本文独立定义的官能化亚氨基,(4)独立地定义如本文的官能化烷基,(5)独立定义的官能化酰基 如本文所述,(6)如本文独立定义的官能化杂环或(7)如本文独立定义的官能化(杂环)烷基。 Ø
-
公开(公告)号:EP0342541A2
公开(公告)日:1989-11-23
申请号:EP89108590.4
申请日:1989-05-12
Applicant: ABBOTT LABORATORIES
Inventor: Kempf, Dale J. , Plattner, Jacob J. , Norbeck, Daniel W. , Baker, William R. , Fung, Anthony K. L. , Boyd, Steven A. , Erickson, John W. , Crowley, Steven R.
IPC: C07K5/02 , C07K5/04 , A61K37/64 , C07C103/49 , C07D307/22 , C07C125/065 , C07D295/20 , C07D263/38 , C07D307/68
CPC classification number: C07D239/10 , A61K38/00 , C07C271/22 , C07C317/44 , C07C323/60 , C07C2601/06 , C07C2601/14 , C07D233/32 , C07D263/06 , C07D263/20 , C07D263/22 , C07D263/24 , C07D263/26 , C07D265/06 , C07D273/00 , C07D295/205 , C07D295/215 , C07D307/58 , C07D307/68 , C07D317/36 , C07D333/38 , C07D413/06 , C07K5/06026 , C07K5/06043 , C07K5/06078 , C07K5/101 , C07K5/1016 , C07K7/02
Abstract: A retroviral protease inhibiting compound of the formula:
or a pharmaceutically acceptable salt, prodrug or ester thereof.Abstract translation: 具有下式的逆转录病毒蛋白酶抑制化合物:
或其药学上可接受的盐,前药或酯。 -
5.Intermediates for preparating non-peptide retroviral protease inhibitors 失效
Title translation: Zvischenprodukte zur Herstellung von non-peptiden retroviralproteasehemmenden Verbindungen公开(公告)号:EP0839798B1
公开(公告)日:2005-08-17
申请号:EP97119700.9
申请日:1990-05-17
Applicant: ABBOTT LABORATORIES
Inventor: Kempf, Dale J. , Norbeck, Daniel W. , Erickson, John W. , Sham, Hing Leung , Codacovi, Lynn M. , Plattner, Jacob J.
IPC: C07C215/18 , C07C271/20 , C07C237/10 , C07D303/40 , C07D303/46
CPC classification number: C07D207/08 , A61K38/00 , C07C33/46 , C07C43/164 , C07C43/1742 , C07C43/2055 , C07C43/215 , C07C43/23 , C07C43/30 , C07C43/315 , C07C45/004 , C07C45/29 , C07C45/567 , C07C45/59 , C07C45/62 , C07C45/673 , C07C45/74 , C07C53/134 , C07C69/34 , C07C69/65 , C07C69/732 , C07C211/27 , C07C215/18 , C07C215/20 , C07C215/28 , C07C229/08 , C07C229/26 , C07C229/34 , C07C233/36 , C07C233/40 , C07C235/10 , C07C235/12 , C07C235/34 , C07C235/78 , C07C237/10 , C07C237/20 , C07C237/22 , C07C239/10 , C07C239/18 , C07C239/20 , C07C247/10 , C07C251/40 , C07C271/20 , C07C271/22 , C07C271/34 , C07C275/16 , C07C275/24 , C07C311/03 , C07C311/13 , C07C311/18 , C07C317/10 , C07C317/28 , C07C317/44 , C07C323/12 , C07C323/25 , C07C381/00 , C07C2601/14 , C07D207/24 , C07D209/42 , C07D211/62 , C07D213/30 , C07D213/40 , C07D213/42 , C07D213/56 , C07D213/70 , C07D213/81 , C07D213/82 , C07D215/16 , C07D217/16 , C07D217/26 , C07D231/12 , C07D233/56 , C07D233/84 , C07D239/38 , C07D249/08 , C07D263/32 , C07D277/24 , C07D277/28 , C07D277/36 , C07D277/42 , C07D277/56 , C07D295/088 , C07D295/15 , C07D295/155 , C07D295/185 , C07D295/205 , C07D295/215 , C07D295/26 , C07D303/04 , C07D303/22 , C07D303/36 , C07D303/48 , C07D307/42 , C07D317/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07F9/3241 , C07F9/5333 , C07K5/021 , C07K5/06043 , C07K5/06052 , C07K5/06139 , Y02P20/55 , C07C49/233 , C07C49/255 , C07C49/215 , C07C49/245 , C07C49/235 , C07C49/223
-
6.Intermediates for preparating non-peptide retroviral protease inhibitors 失效
Title translation: 用于制备非肽逆转录病毒蛋白酶抑制剂的中间体公开(公告)号:EP0839798A3
公开(公告)日:1998-10-28
申请号:EP97119700.9
申请日:1990-05-17
Applicant: ABBOTT LABORATORIES
Inventor: Kempf, Dale J. , Norbeck, Daniel W. , Erickson, John W. , Sham, Hing Leung , Codacovi, Lynn M. , Plattner, Jacob J.
IPC: C07C215/18 , C07C271/20 , C07C237/10 , C07D303/40 , C07D303/46
Abstract: Intermediates, for preparing non-peptide retroviral protease inhibitors, said intermediates having the formula:
or an acid addition salt thereof or an N-protected derivative thereof wherein at each occurrence the N-protecting group is independently selected from the group consisting of formyl, acetyl, pivaloyl, t-butylacetyl, t-butyloxycarbonyl, benzyloxycarbonyl, benzyl and isopropylaminocarbonyl; or said intermediates being selected from:
(2S,3R,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4R,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4R,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4R,5S)-2-(N-(t-butyloxy)carbonyl)amino)-5-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; 2-(N-benzyl-N-(benzyloxycarbonyl)amino)-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; 2-amino-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; and 2,5-di-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide;
or an acid addition salt thereof.Abstract translation: 用于制备非肽逆转录病毒蛋白酶抑制剂的中间体,所述中间体具有下式:或其酸加成盐或其N-保护的衍生物,其中在每次出现时N-保护基独立地选自甲酰基,乙酰基 ,新戊酰基,叔丁基乙酰基,叔丁氧基羰基,苄氧基羰基,苄基和异丙基氨基羰基; 或所述中间体选自:(2S,3R,4S,5S)-2,5-二 - (N-(Cbz-缬氨酰基)氨基)-3,4-二羟基-1,6-二苯基己烷; (2S,3S,4S,5S)-2,5-二 - (N-(Cbz基缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷; (2S,3R,4R,5S)-2,5-二 - (N-(Cbz基缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷; (2S,3S,4S,5S)-2,5-二 - (N-(缬氨酰基)氨基)-3,4-二羟基-1,6-二苯基己烷; (2S,3R,4S,5S)-2,5-二 - (N-(缬氨酰基)氨基)-3,4-二羟基-1,6-二苯基己烷; (2S,3R,4R,5S)-2,5-二 - (N-(缬氨酰基)氨基)-3,4-二羟基-1,6-二苯基己烷; (2S,3S,4R,5S)-2-(N-(叔丁氧基)羰基)氨基)-5-(N-(Cbz基缬氨酰)氨基)-3,4-二羟基-1,6-二苯基己烷; 2-(N-苄基-N-(苄氧羰基)氨基)-5-(叔丁氧羰)-1,6-二苯基 - 3-己烯-3,4-氧化物; 2-氨基-5-(叔丁氧羰)-1,6-二苯基 - 3-己烯-3,4-氧化物; 和2,5-二 - (叔丁氧基羰基氨基)-1,6-二苯基-3-己烯-3,4-氧化物; 或其酸加成盐。
-
公开(公告)号:EP0342541A3
公开(公告)日:1991-11-06
申请号:EP89108590.4
申请日:1989-05-12
Applicant: ABBOTT LABORATORIES
Inventor: Kempf, Dale J. , Plattner, Jacob J. , Norbeck, Daniel W. , Baker, William R. , Fung, Anthony K. L. , Boyd, Steven A. , Erickson, John W. , Crowley, Steven R.
IPC: C07K5/02 , C07K5/04 , A61K37/64 , C07C103/49 , C07D307/22 , C07C125/065 , C07D295/20 , C07D263/38 , C07D307/68
CPC classification number: C07D239/10 , A61K38/00 , C07C271/22 , C07C317/44 , C07C323/60 , C07C2601/06 , C07C2601/14 , C07D233/32 , C07D263/06 , C07D263/20 , C07D263/22 , C07D263/24 , C07D263/26 , C07D265/06 , C07D273/00 , C07D295/205 , C07D295/215 , C07D307/58 , C07D307/68 , C07D317/36 , C07D333/38 , C07D413/06 , C07K5/06026 , C07K5/06043 , C07K5/06078 , C07K5/101 , C07K5/1016 , C07K7/02
Abstract: A retroviral protease inhibiting compound of the formula:
or a pharmaceutically acceptable salt, prodrug or ester thereof.
-
-
-
-
-
-